165 related articles for article (PubMed ID: 9846585)
1. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model.
Mandl CW; Aberle JH; Aberle SW; Holzmann H; Allison SL; Heinz FX
Nat Med; 1998 Dec; 4(12):1438-40. PubMed ID: 9846585
[TBL] [Abstract][Full Text] [Related]
2. Infectious cDNA clone of attenuated Langat tick-borne flavivirus (strain E5) and a 3' deletion mutant constructed from it exhibit decreased neuroinvasiveness in immunodeficient mice.
Pletnev AG
Virology; 2001 Apr; 282(2):288-300. PubMed ID: 11289811
[TBL] [Abstract][Full Text] [Related]
3. Mimicking live flavivirus immunization with a noninfectious RNA vaccine.
Kofler RM; Aberle JH; Aberle SW; Allison SL; Heinz FX; Mandl CW
Proc Natl Acad Sci U S A; 2004 Feb; 101(7):1951-6. PubMed ID: 14769933
[TBL] [Abstract][Full Text] [Related]
4. Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus.
Aberle JH; Aberle SW; Kofler RM; Mandl CW
J Virol; 2005 Dec; 79(24):15107-13. PubMed ID: 16306582
[TBL] [Abstract][Full Text] [Related]
5. Safety evaluation of chimeric Langat/Dengue 4 flavivirus, a live vaccine candidate against tick-borne encephalitis.
Pripuzova NS; Tereshkina NV; Gmyl LV; Dzhivanyan TI; Rumyantsev AA; Romanova LIu; Mustafina AN; Lashkevich VA; Karganova GG
J Med Virol; 2009 Oct; 81(10):1777-85. PubMed ID: 19697399
[TBL] [Abstract][Full Text] [Related]
6. Live virus vaccines: something old, something new, something borrowed..
Dubensky TW; Polo JM; Liu MA
Nat Med; 1998 Dec; 4(12):1357-8. PubMed ID: 9846565
[No Abstract] [Full Text] [Related]
7. Evaluation of tick-borne encephalitis DNA vaccines in monkeys.
Schmaljohn C; Custer D; VanderZanden L; Spik K; Rossi C; Bray M
Virology; 1999 Oct; 263(1):166-74. PubMed ID: 10544091
[TBL] [Abstract][Full Text] [Related]
8. Envelope exchange for the generation of live-attenuated arenavirus vaccines.
Bergthaler A; Gerber NU; Merkler D; Horvath E; de la Torre JC; Pinschewer DD
PLoS Pathog; 2006 Jun; 2(6):e51. PubMed ID: 16751848
[TBL] [Abstract][Full Text] [Related]
9. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus.
Fleeton MN; Chen M; Berglund P; Rhodes G; Parker SE; Murphy M; Atkins GJ; Liljeström P
J Infect Dis; 2001 May; 183(9):1395-8. PubMed ID: 11294672
[TBL] [Abstract][Full Text] [Related]
10. A study of systems for delivering antigens and plasmid DNA for intranasal immunization against tick-borne encephalitis virus.
Goncharova EP; Ryzhikov AB; Bulychev LE; Sizov AA; Lebedev LR; Poryvaev VD; Karpenko LI; Il'ichev AA
Wien Klin Wochenschr; 2002 Jul; 114(13-14):630-5. PubMed ID: 12422616
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Langat/Dengue viruses protect mice from heterologous challenge with the highly virulent strains of tick-borne encephalitis virus.
Pletnev AG; Karganova GG; Dzhivanyan TI; Lashkevich VA; Bray M
Virology; 2000 Aug; 274(1):26-31. PubMed ID: 10936085
[TBL] [Abstract][Full Text] [Related]
12. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines.
Brandler S; Tangy F
Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):271-91. PubMed ID: 17869338
[TBL] [Abstract][Full Text] [Related]
13. Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys.
Rumyantsev AA; Chanock RM; Murphy BR; Pletnev AG
Vaccine; 2006 Jan; 24(2):133-43. PubMed ID: 16115704
[TBL] [Abstract][Full Text] [Related]
14. A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms.
Aberle JH; Aberle SW; Allison SL; Stiasny K; Ecker M; Mandl CW; Berger R; Heinz FX
J Immunol; 1999 Dec; 163(12):6756-61. PubMed ID: 10586074
[TBL] [Abstract][Full Text] [Related]
15. [Immunogenicity and protective properties for mice of the formalin-inactivated tick-borne encephalitis virus].
Gut W; Jarzabek Z; Sadowski W; Kańtoch M
Med Dosw Mikrobiol; 1986; 38(4):234-40. PubMed ID: 3561097
[No Abstract] [Full Text] [Related]
16. Potential use of attenuated langat E5 virus as a live vaccine -- long term protection against Russian spring-summer encephalitis virus in mice.
Thind S
J Hyg Epidemiol Microbiol Immunol; 1981; 25(2):155-62. PubMed ID: 6265549
[TBL] [Abstract][Full Text] [Related]
17. Flavivirus immunization with capsid-deletion mutants: basics, benefits, and barriers.
Mandl CW
Viral Immunol; 2004; 17(4):461-72. PubMed ID: 15671744
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Internal Ribosome Entry Site/MicroRNA-Based Approach for Flavivirus Attenuation and Live Vaccine Development.
Tsetsarkin KA; Liu G; Volkova E; Pletnev AG
mBio; 2017 Apr; 8(2):. PubMed ID: 28420742
[TBL] [Abstract][Full Text] [Related]
19. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions.
Veits J; Römer-Oberdörfer A; Helferich D; Durban M; Suezer Y; Sutter G; Mettenleiter TC
Vaccine; 2008 Mar; 26(13):1688-96. PubMed ID: 18291561
[TBL] [Abstract][Full Text] [Related]
20. Engineering attenuated virus vaccines by controlling replication fidelity.
Vignuzzi M; Wendt E; Andino R
Nat Med; 2008 Feb; 14(2):154-61. PubMed ID: 18246077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
